Mission Statement, Vision, & Core Values of PetVivo Holdings, Inc. (PETV)

You're looking at PetVivo Holdings, Inc. (PETV) because their core product, Spryng, is gaining traction, driving Q2 fiscal year 2026 revenue up 51% to $303,000 as they pivot from the equine market to the larger companion animal segment. But a mission statement isn't just marketing fluff; it's the operational North Star, and you need to know if their stated purpose can bridge the gap between their record $1.1 million in fiscal year 2025 revenue and their still-significant $8 million net loss for the same period. Does their vision for innovative therapeutics defintely align with the hard reality of a highly competitive, rapidly growing $11.3 billion U.S. animal health market, or are they just selling a good story?

PetVivo Holdings, Inc. (PETV) Overview

PetVivo Holdings, Inc. is a biomedical device company that focuses on adapting human medical technology for the animal health market, a strategy that helps them accelerate product commercialization. Established in 2009 in Minneapolis, Minnesota, the company has built a business around creating innovative, non-pharmaceutical solutions for companion animals, primarily dogs and horses. They've been operational since 2017 and have since focused on building a strong intellectual property portfolio.

Their flagship product is Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection (meaning, it goes directly into the joint) designed to manage lameness and joint afflictions like osteoarthritis. This product uses proprietary, patented micro-cushion technology to address the root cause of joint issues. PetVivo Holdings, Inc. also recently expanded its offerings with PrecisePRP, a breakthrough regenerative health product that can be used alongside Spryng. This dual-product approach is now available in over 800 veterinary clinics across all 50 states.

For the full fiscal year 2025, which ended on March 31, 2025, the company reported record net revenue of approximately $1.13 million. This revenue represents a key milestone, showing the commercial traction of their core product line as they continue to expand their distributor network and sales force.

Record Revenue and Market Expansion in Latest Reports

If you're looking at the near-term financials, the numbers from the latest reporting period, Fiscal Q2 2026 (ending September 30, 2025), show a clear acceleration in product adoption. Revenues for the quarter totaled $303,000, marking a 51% increase year-over-year and setting a record for a second fiscal quarter. This growth is defintely a result of their strategic shift.

Here's the quick math on product sales: distributor network sales, which are a strong indicator of market penetration, increased 35% to $237,000 in Q2 2026, accounting for 75% of total revenue. This surge was primarily driven by two things: the introduction of the new PrecisePRP product line and the successful expansion from the large equine market into the larger, faster-growing companion animal market. Gross profit for the quarter was a solid $220,000, representing a gross margin of 72.6%.

Still, it's important to be a realist. While revenue is climbing, the company continues to invest heavily in growth, reporting a net loss of $3.0 million for the quarter. What this estimate hides is that total liabilities were significantly reduced by 79% to $1.1 million as of September 30, 2025, a sign of improved balance sheet management.

• Q2 FY2026 Revenue: $303,000 (up 51% YoY).
• Distributor Sales: $237,000 (75% of total revenue).
• Total Liabilities: Reduced to $1.1 million (down 79%).

PetVivo Holdings, Inc.'s Position in the Veterinary Medical Device Industry

PetVivo Holdings, Inc. is emerging as a leader not just through product sales, but through innovation that reshapes the veterinary landscape. The company holds a robust portfolio of approximately 21 patents protecting its biomaterials and products, which gives them a significant competitive moat in the biomedical device space. Their core strategy is to translate proven human therapies for veterinary use, which allows them to bypass lengthy regulatory timelines and get innovative products like Spryng to market faster.

Also, in a move that maps near-term opportunity to clear action, the company recently secured an exclusive 10-year licensing agreement for Agentic Pet AI technology. This positions them at the intersection of veterinary care and the projected $4.9 billion US veterinary AI market. The goal is simple: use AI to reduce client acquisition costs for veterinary practices by a massive 90% to 98%, while simultaneously connecting with the exploding Gen Z pet parent demographic. This kind of forward-thinking, tech-enabled strategy is why PetVivo Holdings, Inc. is viewed as a company that is revolutionizing veterinary medicine. If you want a deeper dive into the investor profile, you can find more information here: Exploring PetVivo Holdings, Inc. (PETV) Investor Profile: Who's Buying and Why?

PetVivo Holdings, Inc. (PETV) Mission Statement

You're looking for the bedrock of PetVivo Holdings, Inc.'s strategy, and honestly, it all starts with their mission. A company's mission isn't just a plaque on the wall; it's the operating manual that guides every dollar of their $8.1 million operating loss reduction in fiscal year 2025 and every new product launch.

PetVivo's core mission is clear: to improve the lives of animals through the development, commercialization, and licensing of innovative medical devices and therapeutics. This focus is what drives their strategic decisions, like the expansion of their lead product, Spryng® with OsteoCushion™ Technology, into the larger companion animal market, which helped push fiscal 2025 revenues to a record $1.1 million.

Here's the quick math: if your mission is about improving lives through innovation, you have to invest in the science. Their commitment to scientific rigor and product quality directly translates into their impressive gross margin of 87.8% for fiscal 2025. That's a strong signal of product value and cost-efficiency in their manufacturing process.

Component 1: Advancing Animal Health Through Innovative Therapeutics

The first crucial component of the mission is the commitment to innovative medical devices and therapeutics. PetVivo isn't just selling a supplement; they're a biomedical device company leveraging proprietary technology. Their strategy is smart: they adapt successful human therapies for use in animals, which is a capital- and time-efficient way to bring new treatments to market.

This innovation is best seen in their product line. Their flagship product, Spryng® with OsteoCushion™ Technology, is an intra-articular injection (a shot into the joint) designed to manage lameness and osteoarthritis in cats, dogs, and horses. Plus, the exclusive licensing agreement signed with VetStem in February 2025 for PrecisePRP®-a first-in-class, off-the-shelf platelet-rich plasma product-shows they are defintely serious about expanding their therapeutic platform.

This focus on next-generation solutions is why they've been able to penetrate the market so quickly. They are committed to science, not just sales.

• Spryng® treats joint pain, not just masks symptoms.
• PrecisePRP® is an easy-to-use, off-the-shelf regenerative product.
• The company holds a portfolio of 12 patents protecting its biomaterials and products.

Component 2: Focus on the Companion Animal Market

While they started with a strong presence in the equine market, the mission's execution has pivoted to the larger, faster-growing companion animal market. This strategic shift is a direct response to market opportunity, and it's paying off. Fiscal 2025 saw a revenue increase of 17% to $1.1 million, driven primarily by this expansion. The companion animal market is huge, and PetVivo is positioning itself right in the middle of it.

The company's success is measurable in adoption: Spryng® has been administered by more than 1,000 veterinary clinics across all 50 states since its introduction. That's a massive operational milestone that proves veterinarians trust the quality and efficacy of the product. Also, PetVivo is now addressing the pet-parent boom, especially with Gen Z, who treat their pets as children. Their new strategic alliance with Digital Landia to integrate Agentic Pet AI technology is a move to capture this demographic, potentially reducing client acquisition costs from over $50 to as low as $1.50 per targeted outreach. That's a game-changer for market reach.

You can learn more about the market dynamics and the investors driving this growth by reading Exploring PetVivo Holdings, Inc. (PETV) Investor Profile: Who's Buying and Why?

Component 3: Commitment to Quality, Integrity, and Compassion

The mission is underpinned by a set of core values, with Quality, Integrity, and Compassion being paramount. Quality isn't just a talking point; it's a financial driver. The company's high gross margin of 87.8% in fiscal 2025 is a testament to the premium nature and cost control of their high-quality manufacturing.

The commitment to compassion is evident in the products themselves-they aim to improve the quality of life for animals by addressing debilitating conditions like osteoarthritis. Integrity and transparency are also core, demonstrated by their uplift from the OTCQB to the OTCQX market in late 2025, which requires meeting higher financial standards and following best practices in corporate governance.

This ethical foundation is a key risk mitigator for investors. When a company is committed to quality, you see it in the low rate of product issues and the high rate of veterinarian adoption, which, in PetVivo's case, is over 1,000 clinics using their lead product. They also increased R&D investment in fiscal 2025, even while reducing operating loss, showing they prioritize innovation over short-term savings.

PetVivo Holdings, Inc. (PETV) Vision Statement

You're looking for the anchor points of a company's strategy, and for PetVivo Holdings, Inc., it's all mapped out in their vision: to be a leading provider of innovative animal health solutions that enhance the quality of life for pets worldwide. This isn't just a feel-good statement; it's a clear roadmap for their product development, market expansion, and financial focus, especially as they move past their fiscal year 2025 (FY2025) performance.

The company's mission, which is the daily work of that vision, is to improve the lives of animals through the development, commercialization, and licensing of innovative medical devices and therapeutics. This mission is directly supported by the strategic shift we saw in FY2025, moving from a primary focus on the equine market to the much larger companion animal market, which is where the real growth is.

Building a Leading Provider of Innovative Animal Health Solutions

The core of PetVivo Holdings, Inc.'s vision is to lead with innovation, which means constantly investing in their proprietary technology. In fiscal 2025, the company demonstrated this commitment by spending $1,583,250 on Research and Development (R&D) expenses, a figure that funds the clinical studies and commercial launch support for products like Spryng with OsteoCushion Technology.

This focus on biomedical devices and therapeutics is their competitive edge. It's about leveraging human therapies for animals in a capital- and time-efficient way. The company's flagship product, Spryng, for managing joint-related conditions like osteoarthritis, is now being used by over 1,000 veterinary clinics across the United States.

• Innovate to lead, not just compete.
• R&D spending supports a 21-patent portfolio.
• Strategic partnerships, like the one for PrecisePRP, expand the product line.

To be fair, this investment comes at a cost; the operating loss for FY2025 was still high at $8.1 million, but that was a 24% improvement over the previous year, showing their cost reduction programs are defintely working.

Enhancing the Quality of Life for Pets

The empathetic heart of the vision is the commitment to animal welfare, which is the ultimate goal of their product line. This is their core value-improving the well-being of dogs, cats, and horses suffering from painful conditions like lameness and joint pain. The product's success is measured by its adoption, and the preliminary FY2025 results show revenues increased 17% to a record $1.1 million.

Here's the quick math on their operational efficiency: gross profit for the year climbed 15% to $995,000, maintaining a very strong gross margin of 87.8%. That high margin is a key indicator that the product, which is a veterinarian-administered injectable, is highly valued and cost-effective to produce. When a product is that effective and profitable, it means more animals get access to better care, directly fulfilling the quality-of-life promise.

The company's strategic shift is paying off in the companion animal market, and you can see more about this foundational strategy at PetVivo Holdings, Inc. (PETV): History, Ownership, Mission, How It Works & Makes Money.

Expanding Solutions Worldwide

The final component of the vision is global reach. The strategy to expand beyond the U.S. domestic market is crucial for sustained growth, especially since the company's FY2025 revenue of $1.1 million is small in the context of the overall animal health market. The expansion is being driven by a growing national distributor network, which saw sales jump 31% to $958,000 in FY2025, accounting for 85% of total revenues.

This reliance on distributors like Vedco and Clipper Distributing is the mechanism for going global. It's a capital-light way to scale. For instance, the company has already entered the international market through a distribution agreement in Mexico. Plus, the recent exclusive 10-year white-label licensing agreement for Agentic Pet AI technology with Digital Landia Holding Corp, announced in October 2025, is a strategic bet to capture the tech-savvy Gen Z pet parent demographic and enter a $4.9 billion US veterinary AI market.

What this estimate hides is the execution risk of international expansion and the successful integration of new technology, but the foundation is a strong domestic distribution base. They have to keep that momentum going.

PetVivo Holdings, Inc. (PETV) Core Values

You're looking for the bedrock of PetVivo Holdings, Inc.'s operations-the principles that translate into their financial and strategic decisions. For a biomedical company, those values aren't just words on a wall; they're the engine for innovation and fiscal discipline. The company's focus is clear: advance animal health while building a sustainable business, which is exactly what you see in their fiscal 2025 results.

Here's the quick math: record revenues of $1.1 million for the fiscal year ended March 31, 2025, up 17% year-over-year, show their core values are driving market traction.

This value is the company's lifeblood. PetVivo Holdings, Inc. is fundamentally dedicated to improving the quality of life for companion animals, especially by addressing debilitating conditions like osteoarthritis (OA). This commitment drives their entire product development pipeline, translating human therapies for veterinary use in a capital-efficient way.

Their lead product, Spryng with OsteoCushion Technology, is a prime example. It's an innovative, minimally invasive medical device designed to treat lameness and joint pain in dogs and horses. By the end of fiscal year 2025, this product had been used by more than 800 veterinary clinics across all 50 US states, showing real-world impact.

Also, the company is actively investing in the next generation of solutions. They are accumulating substantial data for a canine study focused on elbow osteoarthritis, which is defintely a high-impact area for pet owners. That's how you turn a mission statement into a tangible asset.

• Develop non-pharmaceutical, regenerative solutions.
• Expand product use beyond horses to companion animals.
• Advance clinical studies on debilitating conditions.

For a public company, integrity means responsible stewardship of capital and transparent governance. You want to see management using your investment dollars efficiently, especially in a growth-stage biomedical company. PetVivo Holdings, Inc. demonstrated this commitment in fiscal 2025 through a rigorous strategic corporate restructuring and cost reduction program.

This fiscal discipline resulted in a significant improvement on the bottom line. The operating loss for the fiscal year ended March 31, 2025, decreased by 24% to $8.1 million. That's a clear action showing they are focused on the long-term health of the business, not just top-line growth. Furthermore, the company dramatically improved its balance sheet, with total liabilities decreasing by a massive 79% to $1.1 million at September 30, 2025, down from $5.1 million at the end of the 2025 fiscal year. That reduction in debt and derivative liabilities is a concrete sign of financial integrity and improved stakeholder value.

A great product is useless if veterinarians and pet owners can't access it easily. PetVivo Holdings, Inc. views customer satisfaction through the lens of market expansion and education, ensuring their innovative therapeutics are accessible to the veterinary community.

In fiscal 2025, the company's push to expand its national distributor network was key. They added two national distributors, which helped drive national distributor network sales up 31% to $958,000, representing 85% of their total revenue. This shift to a distributor model makes the product more readily available to clinics.

In October 2025, the company solidified this value by entering a Vendor Partner Agreement with Veterinary Growth Partners (VGP), an organization that supports over 7,300 veterinary members across the US. This partnership directly accelerates their mission to improve animal lives through accessible treatment solutions. Also, they are investing in the professionals who use their products, offering new RACE-Approved Continuing Education (CE) courses focused on osteoarthritis and regenerative therapies. You can read more about the company's financial stability and market position in Breaking Down PetVivo Holdings, Inc. (PETV) Financial Health: Key Insights for Investors.